Cellmid
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WACellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss.
The company holds global intellectual properties relating to novel targets midkine and FGF5.
Contact Details
Suite 204, Level 2, 55 Clarence Street, SYDNEY NSW 2000
02 9221 6830
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 831st |  | Cellmid | $6.8m |
| 973rd | | Hexima | $1.5m |
| 974th | | Arovella Therapeutics | $1.5m |
| 976th | | Nyrada Inc | $1.4m |
| 977th | | Spark Infrastructure Group | $1.4m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Teruko Fujii, | 04 Nov 2021 |
| NEW ROLE: Sarah Eck-Thompson, Alternate Director for Dennis Eck | 05 Dec 2020 |
| NEW ROLE: Brian McGee, CEO, North America | 24 Nov 2020 |
| NEW ROLE: Bart Wuurman, Chief Executive Officer | 24 Nov 2020 |
| NEW ROLE: Martin Cross, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Lee Tamplin, Company Secretary | 03 Nov 2020 |
| NEW ROLE: David King, Non-Executive Chair | 03 Nov 2020 |
| NEW ROLE: Dennis Eck, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Bruce Gordon, Non-Executive Director, Chair since 2021 | 03 Nov 2020 |
